Zabdeno® booster for hemorrhagic fever, ebola

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 13 Nov 2023: Trial registered, NCT06126822
  2. 25 Feb 2025: Trial started, NCT06126822

The trials

NCT06126822: Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination with the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRC

State
Under way
Phase
Phase 3
People
624 planned
Started
25 Feb 2025
Primary completion
Oct 2026
Arms
Zabdeno/Mvabea® vaccinated - Zabdeno® booster, Ervebo® vaccinated - Zabdeno® booster
Results
None posted
  1. 13 Nov 2023: Trial registered
  2. 25 Feb 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.